BIOMAT Database Logo BIOMAT Database Logo

Zidovudine therapy and myopathies associated with human immunodeficiency virus infection. 1994

P Chariot, and E Ruet, and R Gherardi

UI MeSH Term Description Entries
D009135 Muscular Diseases Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE. Muscle Disorders,Myopathies,Myopathic Conditions,Muscle Disorder,Muscular Disease,Myopathic Condition,Myopathy
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

P Chariot, and E Ruet, and R Gherardi
Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished?
May 1993, Neurology,
P Chariot, and E Ruet, and R Gherardi
Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies.
December 1991, Human pathology,
P Chariot, and E Ruet, and R Gherardi
Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection.
February 1994, Pediatrics,
P Chariot, and E Ruet, and R Gherardi
Zidovudine and nephropathy with human immunodeficiency virus (HIV) infection.
November 1989, Annals of internal medicine,
P Chariot, and E Ruet, and R Gherardi
Human immunodeficiency virus infection in pregnant women, transmission and zidovudine therapy.
July 2001, European journal of obstetrics, gynecology, and reproductive biology,
P Chariot, and E Ruet, and R Gherardi
[Nephropathie associated with human immunodeficiency virus infection: possible therapeutic value of zidovudine].
November 1991, Presse medicale (Paris, France : 1983),
P Chariot, and E Ruet, and R Gherardi
[Treatment with zidovudine of thrombopenia associated with human immunodeficiency virus infection. Changes in erythropoiesis].
November 1989, Medicina clinica,
P Chariot, and E Ruet, and R Gherardi
[Antiviral drugs other than zidovudine and immunomodulator therapy for human immunodeficiency virus infection].
July 1989, Mikrobiyoloji bulteni,
P Chariot, and E Ruet, and R Gherardi
Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
August 1993, Annals of neurology,
P Chariot, and E Ruet, and R Gherardi
Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection.
June 1994, The Journal of infectious diseases,
Copied contents to your clipboard!